business
Goldman Sachs sets new Biogen stock price target on bold Alzheimer's bet
Key takeaways
- Goldman Sachs sets new Biogen stock price target on bold Alzheimer's bet Peace Longe Mon, May 18, 2026 at 3:33 AM GMT+7 7 min read BIIB GS Biogen (NASDAQ: BIIB) has had a rocky few years.
- So when Goldman Sachs steps up with a price target hike to $250, it's worth asking what the bank is actually seeing.
- The short answer: Leqembi, Biogen's Alzheimer's treatment, is delivering.
Goldman Sachs sets new Biogen stock price target on bold Alzheimer's bet Peace Longe Mon, May 18, 2026 at 3:33 AM GMT+7 7 min read BIIB GS Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics and biosimilars, revenue has trended down, and the stock spent much of 2025 trading near multi-year lows.
So when Goldman Sachs steps up with a price target hike to $250, it's worth asking what the bank is actually seeing.
The short answer: Leqembi, Biogen's Alzheimer's treatment, is delivering. And the case for the stock goes beyond today's sales figures, hinging on what the next 18 months could look like if several catalysts land on schedule.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop